share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4:持股变动声明
SEC announcement ·  03/12 17:49
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, engaged in a series of stock transactions from March 10 to March 12, 2024. Kulkarni acquired a total of 28,250 common shares through the exercise of derivative securities. Concurrently, he sold 14,385 shares in open market transactions. The sales occurred on March 11 and March 12, with prices ranging from $74.44 to $78.26 per share, resulting in a total market value of $1,108,263.04. Following these transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, he has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT. The transactions are reported as in progress.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, engaged in a series of stock transactions from March 10 to March 12, 2024. Kulkarni acquired a total of 28,250 common shares through the exercise of derivative securities. Concurrently, he sold 14,385 shares in open market transactions. The sales occurred on March 11 and March 12, with prices ranging from $74.44 to $78.26 per share, resulting in a total market value of $1,108,263.04. Following these transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, he has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT. The transactions are reported as in progress.
CRISPR Therapeutics AG的首席执行官萨玛斯·库尔卡尼在2024年3月10日至3月12日期间进行了一系列股票交易。库尔卡尼通过行使衍生证券共收购了28,250股普通股。同时,他在公开市场交易中出售了14,385股股票。销售发生在3月11日和3月12日,价格从每股74.44美元到78.26美元不等,总市值为1,108,263.04美元。在这些交易之后,库尔卡尼直接持有CRISPR Therapeutics的208,122股股份。此外,他通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。交易报告为正在进行中。
CRISPR Therapeutics AG的首席执行官萨玛斯·库尔卡尼在2024年3月10日至3月12日期间进行了一系列股票交易。库尔卡尼通过行使衍生证券共收购了28,250股普通股。同时,他在公开市场交易中出售了14,385股股票。销售发生在3月11日和3月12日,价格从每股74.44美元到78.26美元不等,总市值为1,108,263.04美元。在这些交易之后,库尔卡尼直接持有CRISPR Therapeutics的208,122股股份。此外,他通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。交易报告为正在进行中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息